AMWL — American Well Corporation

Amwell (AMWL) Q2 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Revenue: $52 million, down 26.6% year-over-year.
• Subscription Revenue: $25.7 million, a decline of 36.5% year-over-year but up 3.2% sequentially.
• Amwell Medical Group (AMG) Visit Revenue: $24.4 million, up 7.4% year-over-year, with 315,000 visits.
• Adjusted EBITDA: Loss of $1.15 million, an improvement from a loss of $4.7 million in Q2 2025.
• Operating Loss: $9.6 million, down from $20.4 million year-over-year.
• Cash Position: $196 million in cash and marketable securities, with no debt.

2. Strategic Updates and Business Highlights

• Amwell received an intent to award notice for a sole-source contract from the Defense Health Agency (DHA), indicating a deepening partnership and potential for long-term revenue stability.
• Subscription revenue now constitutes over 50% of total revenue, reflecting a shift towards more stable, recurring revenue streams.
• The company is focusing on a unified platform strategy to address market fragmentation, allowing clients to streamline their technology needs and improve patient engagement.
• A recent study published in Nature Human Behaviour validated the effectiveness of Amwell’s SilverCloud behavioral health program, showing improved engagement and reduced costs.

3. Forward Guidance and Outlook

• Q3 2026 Revenue Guidance: Expected between $46 million and $48 million.
• Full Year 2026 Revenue Guidance: Narrowed to $200 million to $205 million, with an adjusted EBITDA loss expected between $9 million and $7 million.
• Amwell aims for positive cash flow from operations and adjusted EBITDA breakeven by Q4 2026.

4. Bad News, Challenges, or Points of Concern

• Total revenue declined significantly year-over-year, primarily due to churn and a one-time revenue benefit from the previous year.
• Subscription revenue continues to face challenges, with a notable decline in the year-over-year metrics.
• The company is navigating a competitive landscape with increasing pressure on payers to control costs and improve outcomes, which could affect future growth if not addressed effectively.

5. Notable Q&A Insights

• The DHA contract is expected to provide greater contract visibility and potential for additional services, although specifics on revenue from this contract are still being negotiated.
• Amwell is actively working on reintroducing itself to health plans, leveraging the DHA contract to enhance credibility and attract new business.
• The company is focused on maintaining a lean operational structure while investing in AI to improve efficiency and service delivery.
• There is ongoing interest from both existing and new customers, driven by the need for consolidated and efficient healthcare solutions amidst rising costs and vendor fatigue.

Overall, Amwell is making progress towards financial stability and growth, with strategic partnerships and a focus on a unified platform, despite facing challenges in revenue and market competition.